Cyclosporin: Revisions in monitoring guidelines and review of current analytical methods

Annals of Clinical Biochemistry

Volumn 39, Issue 5, 2002, Pages 424-435

  Andrews, D J ^a   Cramb, Rob ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A;

ACCURACY; ANALYTIC METHOD; AREA UNDER THE CURVE; CLINICAL TRIAL; CROSS REACTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG MECHANISM; DRUG MONITORING; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMMUNOASSAY; ORGAN TRANSPLANTATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOSPORINE; DRUG MONITORING; GUIDELINES; HUMANS; IMMUNOASSAY; QUALITY CONTROL; REFERENCE VALUES;

EID: 0036729743     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456302320314430     Document Type: Review

References (62)

1. Methodological and clinical aspects of cyclosporin monitoring: Report of the Association of Clinical Biochemists task force
2. New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine
3. Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes
4. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil
5. Cyclosporine
6. Cyclosporin clinical pharmacokinetics
7. Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine
8. Canadian Consensus Meeting on cyclosporine monitoring: Report of the consensus panel
9. Clinical development of a cyclosporine microemulsion in transplantation
10. Induction of immunosuppression by microemulsion cyclosporine in liver transplantation
11. Early use and oral absorption of cyclosporine Neoral after liver transplantation
12. Absorption of cyclosporine Neoral early after liver transplantation: Is it possible to abandon intravenous cyclosporine A application?
13. Anaphylaxis to intravenous cyclosporine and tolerance to oral cyclosporine: Case report and review
14. A microemulsion of cyclosporine without intravenous cyclosporine in liver transplantation
15. Reduced acute rejection after liver transplantation with Neoral-based triple irnmunosuppression
16. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression
17. NOF-11: A one-year randomized double-blind comparison of Neoral versus Sandimmune in pediatric liver transplantation
18. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral
19. Neoral vs Sandimmune: Interim results of a randomized trial of efficacy and safety in preventing acute rejection in new renal transplant recipients
20. Safety, tolerability and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil based formulation of cyclosporine - Results at six months after transplantation
21. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: A randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - Results at 24 months after transplantation
22. Lake Louise consensus conference on cyclosporin monitoring in organ transplantation: Report of the consensus panel
23. The adverse impact of high cyclosporine. Clearance rates on the incidences of acute rejection and graft loss
24. Variations in bioavailability of cyclosporine and relationship to clinical outcome in renal transplant subpopulations
25. Safety and tolerability of cyclosporine and cyclosporine microemulsion during 18 months of follow-up in stable renal transplant recipients: A report of the Canadian Neoral renal study group
26. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: Results of a prospective, randomized comparison of Neoral and Sandimmune for liver transplantation (NOF-8)
27. Predicting patients' exposure to cyclosporin
28. Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate post-transplant period
29. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation
30. Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients
31. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy
32. Sandimmune to Neoral conversion and value of abbreviated auc monitoring in stable pediatric kidney transplant recipients
33. Suitability of plastic collection tubes for cyclosporine measurements
34. Influence of blood sampling sites on measurement of blood cyclosporine concentration
35. New approaches to Neoral monitoring: Methodological implications
36. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): A critical overview of performance characteristics and comparison with HPLC
37. Current opinions on therapeutic drug monitoring of immunosuppressive drugs
38. Quantitation of cyclosporine A in whole blood using liquid chromatography/tandem mass spectrometry
39. A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry
40. Rapid liquid chromatography-tandem mass spectrometry method for routine analysis of cyclosporin A over an extended concentration range
41. Simple and high-throughput quantification of three major immunosuppressants by liquid chromatography-tandem mass spectrometry
42. Evaluation of Waters' OASIS® HLB 3cc 60mg columns for use in the extraction of cyclosporine A from whole blood
43. Improved high-performance liquid chromatography assay for the determination of cyclosporin A in whole blood
44. A simplified, cost effective HPLC assay for cyclosporine A in whole blood
45. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: How specific is specific?
46. Cyclosporin A: Analytical methodology and factors affecting therapeutic drug monitoring
47. Syva EMIT® cyclosporin assay - A novel whole blood pretreatment reagent
48. Evaluation of the AxSYM CyA assay compared with HPLC, TDx monoclonal and EMIT with both pretreatments
49. Evaluation of the new AxSYM cyclosporine assay: Comparison with TDx monoclonal whole blood and Emit cyclosporine assays
50. Evaluation of four automated methods for determination of whole blood cyclosporine concentration
51. Cyclosporin assays, metabolite cross-reactivity and pharmacokinetic monitoring
52. Multicenter evaluation of the new CEDIA CsA PLUS assay for whole blood cyclosporine
53. Cyclosporin assay using Dimension RxL analyser compared to EMIT assay
54. Evaluation of a no pre-treatment cyclosporine A assay on the Dade Behring Dimension RxL clinical chemistry analyser
55. Considerable lack of agreement between S-FPIA and EMIT cydosporine assay in therapeutic drug monitoring of heart transplant recipients
56. New approaches to cyclosporine monitoring raise further concerns about analytical techniques
57. A comparison of EMIT and FPIA methods for the detection of cyclosporin blood levels: Does impaired liver function make a difference?
58. CSA Immunoassays in comparison to LC-MS/MS, is there a difference between trough (C0) and C2 levels?
59. Effect of assay methodology on pharmacokinetic differences between Neoral® and Sandimmune® formulations
60. The new CEDIA PLUS cyclosporine assay: Beta-site evaluation on the Hitachi 911 automated analyser
61. New CEDIA® non-extraction cyclosporine assay